Pharma BD Deal Intelligence

Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma)

2000 · Asset Purchase · $6.9B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Abbott Laboratories acquired the global pharmaceutical operations of BASF (Knoll Pharmaceuticals) for $6.9 billion in cash. The deal included D2E7, a developmental monoclonal antibody later known as Humira (adalimumab), which became the world's best-selling drug with peak annual sales exceeding $20 billion.

Key facts

Announced Dec 15, 2000
Closed Mar 02, 2001
Deal value $6.9B
Deal type Asset Purchase
Therapeutic area Cardiovascular, Immunology, Metabolic, Oncology
Indications Rheumatoid Arthritis, Obesity, Hypothyroidism
Key assets D2E7 (adalimumab / Humira), Meridia (sibutramine), Synthroid (levothyroxine), Human monoclonal antibody technology platform
Mechanism Anti-TNF-alpha monoclonal antibody, Serotonin-norepinephrine reuptake inhibitor, Thyroid hormone replacement

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals